期刊文献+

布地格福治疗慢性阻塞性肺疾病稳定期的效果研究

Effect Research of Budesonide in Treatment of Stable Chronic Obstructive Pulmonary Disease
下载PDF
导出
摘要 目的探究布地格福在慢性阻塞性肺疾病(COPD)稳定期患者中的治疗效果及对其生活质量、肺功能的影响。方法选取2020年1月-2022年1月广东省梅州市平远县人民医院收治的COPD稳定期患者120例为对象,采取随机数字表法分为两组,各60例。对照组采用沙美特罗替卡松治疗,观察组采取布地格福吸入气雾剂治疗,两组均连续治疗12周。比较两组疗效,不良反应,治疗前、治疗后6个月的肺功能,St George’s呼吸(SGRQ)评分。结果与对照组(80.00%)相比,观察组治疗总有效率(93.33%)较高;与对照组(18.33%)相比,观察组不良反应发生率(5.00%)更低(P<0.05);两组治疗12周后患者肺功能得到提高;观察组用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC高于对照组(P<0.05);治疗后两组SGRQ评分均降低,且观察组低于对照组(P<0.05)。结论COPD稳定期应用布地格福治疗的效果显著,可有效改善患者呼吸症状、肺功能,提升患者生活质量,且不良反应发生率低,值得推广应用。 Objective To investigate curative effect of budesonide on stable patients with chronic obstructive pulmonary disease(COPD)and its influence on life quality and pulmonary function.Method:The paper chose 120 stable COPD patients admitted to Meizhou City Pingyuan County People's Hospital from January 2020 to January 2022 as study objects,and divided them into two groups with random number table method,with 60 cases in each group.Control group was treated with salmeterol and fluticasone,while observation group with budesonide inhalation aerosol.Both groups were treated continuously for 12 weeks.Curative effect,adverse reactions,lung function,and St George's respiratory(SGRQ)scores between two groups was compared before and 6 months after treatment,.Result:Observation group had higher total effective rate of treatment(93.33%)than control group(80.00%),incidence of adverse reactions in observation group(5.00%)was lower than control group(18.33%),(P<0.05).After 12 weeks of treatment,lung function of patients in both groups was improved;forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and FEV1/FVC in observation group was higher than control group(P<0.05).After treatment,SGRQ scores of both groups decreased,those of observation group were lower than control group(P<0.05).Conclusion Budesonide can achieve significant effect in the stable phase of COPD,can improve respiratory symptoms,pulmonary function,life quality of patient effectively,with low incidence of adverse reactions,which is worthy of promotion and application.
作者 谢传洪 XIE Chuanhong(Internal Medicine Department No.2,Meizhou City Pingyuan County The People's Hospital,Meizhou,Guangdong,514600)
出处 《智慧健康》 2023年第10期85-88,共4页 Smart Healthcare
关键词 慢性阻塞性肺疾病 布地格福 生活质量 肺功能 Chronic obstructive pulmonary disease Budesonide Life quality Pulmonary function
  • 相关文献

参考文献9

二级参考文献70

共引文献2209

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部